Kanglitai drug co., ltd
Kanglitai Pharmaceutical Co., Ltd. is a Sino-US joint venture biomedical enterprise. With the concept of "preciseness, pragmatism, high efficiency and innovation" and the mission of "biotechnology benefiting society", it is a research and development biomedical enterprise with * technical level and independent innovation ability.
The company was founded on 20 1 1 by a doctor studying in the United States and a national "Taishan scholar" expert. Is a biomedical high-tech enterprise with independent intellectual property rights. The company has a number of independent intellectual property rights of major inventions officially authorized by the state, a cell bank with independent intellectual property rights, and a research and development platform for recombinant protein drugs that meets GMP management standards.
Among them, the invention of independent intellectual property rights, "Therapeutic agents and compositions for restoring hematopoietic function and their uses", won the advanced and excellent evaluation of the National Institutes of Health of the United States, and is a new frontier technological invention in the world at the same scientific research level and research and development stage as the United States.
At present, more than 95% of China's189,000 drug batches are generic drugs, and there are only more than 30 innovative drugs with independent intellectual property rights, and only 7 internationally recognized innovative drugs. The national 1 bio-innovative drug project invented by the company was supported by the national major new drug creation science and technology in 20 17, and it is the first auxiliary drug for cancer treatment in the world, with broad market prospects. At present, the company has a number of bio-innovative drug projects under research, which are major bio-drug research and development projects supported by the state.
At present, there are experts, Taishan scholars, doctors studying in the United States, graduate students and other scientific research personnel in the R&D team. More than 90% of the company's employees have bachelor's degree or above, and the technical department is led by senior talents, forming a leading biomedical R&D team in China, of which 85% have master's degree or above.
In order to realize the rapid development of ethnic medicine industry and benefit the general public and patients, the company sincerely invites you to join us. Let's forge ahead hand in hand and achieve our career and dreams!